Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Cash from Financing Activities: 2020-2025

Historic Cash from Financing Activities for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $13.8 million.

  • Xeris Biopharma Holdings' Cash from Financing Activities rose 16786.75% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year decrease of 65.10%. This contributed to the annual value of $36.2 million for FY2024, which is 2342.28% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Cash from Financing Activities stood at $13.8 million, which was up 1,370.28% from $942,000 recorded in Q2 2025.
  • Xeris Biopharma Holdings' Cash from Financing Activities' 5-year high stood at $78.2 million during Q1 2022, with a 5-year trough of -$3.1 million in Q1 2025.
  • Moreover, its 3-year median value for Cash from Financing Activities was $398,000 (2024), whereas its average is $4.2 million.
  • Over the last 5 years, Xeris Biopharma Holdings' Cash from Financing Activities had its largest YoY gain of 39,224.80% in 2022, and its largest YoY loss of 18,800.00% in 2022.
  • Over the past 5 years, Xeris Biopharma Holdings' Cash from Financing Activities (Quarterly) stood at $125,000 in 2021, then surged by 39,224.80% to $49.2 million in 2022, then slumped by 102.51% to -$1.2 million in 2023, then soared by 132.25% to $398,000 in 2024, then surged by 16,786.75% to $13.8 million in 2025.
  • Its last three reported values are $13.8 million in Q3 2025, $942,000 for Q2 2025, and -$3.1 million during Q1 2025.